Answers are grounded in this paper and cite their sources.
Breast cancer remains the most common cancer and a leading cause of cancer-related mortality among women worldwide. Identifying reliable biomarkers is essential for improving disease diagnosis and outcomes. This study aimed to evaluate the expression levels of miR-429 and miR-592, along with their respective target genes, FN1 and TOP2A, in breast cancer tissues and to explore their clinical relevance. miR-429 and miR-592 were significantly downregulated ( P < 0.01), while FN1 and TOP2A were upregulated ( P < 0.001) in breast cancer tissues compared to normal tissues. FN1 expression was higher in HER2-positive tumors, and TOP2A was the only marker significantly associated with lymph node metastasis ( P < 0.05). However, these associations were not statistically significant after adjustment for age and BMI using multivariable robust linear regression ( P > 0.05). The expression levels of miR-429 and miR-592 were correlated only in non-tumor tissues ( P <0.001), whereas no significant correlations were observed between marker expression levels or with clinical parameters in either tumor or non-tumor tissues ( P > 0.05). ROC analysis demonstrated high diagnostic potential for TOP2A (AUC = 0.842) and moderate diagnostic potential for FN1 (AUC = 0.75), whereas miR-429 (AUC = 0.664) and miR-592 (AUC = 0.659) showed only modest discriminative ability and may serve as potential auxiliary biomarkers rather than independent diagnostic markers.
No takes yet. Share an insight, caveat, or question.
Kajbaf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: